Research programme: adenosine A3 modulators - Gilead Sciences

Drug Profile

Research programme: adenosine A3 modulators - Gilead Sciences

Alternative Names: Adenosine A3 modulators research programme - Gilead Sciences

Latest Information Update: 18 Jul 2002

Price : $50

At a glance

  • Originator Gilead Sciences; Nonindustrial source
  • Class
  • Mechanism of Action Adenosine A3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Stroke

Most Recent Events

  • 09 Jul 2001 This programme is still in active development
  • 22 Jun 1998 New profile
  • 22 Jun 1998 Preclinical development for Stroke in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top